Probucol - Vyrex

Drug Profile

Probucol - Vyrex

Alternative Names: Panavir

Latest Information Update: 03 Jul 2006

Price : $50

At a glance

  • Originator Vyrex Corporation
  • Class Antihyperlipidaemics; Phenols
  • Mechanism of Action Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Suspended HIV infections
  • Discontinued Cerebral vasospasm

Most Recent Events

  • 31 Dec 2005 Suspended - Phase-I for HIV infections treatment in USA (PO)
  • 31 Mar 2004 Discontinued - Preclinical for Cerebral vasospasm in USA (PO)
  • 17 Sep 2002 Preclinical data from a media release has been added to the Neurological Disorders and Vascular Disorders pharmacodynamics fields
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top